A Once-in-a-Century Shift in Mental Health | Trade to Black

On this episode of Trade to Black, presented by Flowhub, hosts Shadd Dales and Anthony Varrell sit down with Dan Karlin, Chief Medical Officer of Definium Therapeutics (NASDAQ: DFTX), to talk about where the company stands with DT-120, its pharmaceutically optimized LSD program for mental health disorders.Karlin walks through what the Trump administration’s April executive order supporting psychedelic research actually meant for the space, and why he sees it as validation for work Definium has been quietly building toward for over five years. The timing lines up with a bigger shift happening across the industry, including Eli Lilly’s move to acquire Definium competitor Atai Beckley just last week, a signal that big pharma is paying close attention to this category.The conversation gets into the phase three data behind DT-120, including a 17.6% change on the MADRS scale just one week after a single dose, with no adjuvant psychotherapy involved. They also cover the phase two results in generalized anxiety disorder, where a single treatment put roughly half of participants into full remission that held for three months. Karlin points out that no new drug has been approved for generalized anxiety disorder since 2007, which frames just how overdue this category is for something new.He goes as far as calling this potentially the biggest breakthrough in psychiatry in over 120 years, and lays out how Definium thinks about treatment going forward: monitoring patients after a dose and retreating only if symptoms return, rather than pushing a maintenance model. He also talks about where AI fits into their trial process for quality control and how the FDA relationship has evolved under the current regulatory environment.A grounded, detail-heavy conversation for anyone tracking the psychedelic medicine space and Definium Therapeutics specifically.#DefiniumTherapeutics #DFTX #PsychedelicStocks #PsychedelicMedicine #MentalHealthInnovation #Biotech #Psychiatry #ClinicalTrials #FDA #EliLilly #BigPharmaWant to see more Cannabis Reform?🎬    • Why Cannabis Companies Are Backing Trump |...  🎬    • The DEA Hearing Is Over. Now What? | TDR C...  🎬    • Are THC Drinks Replacing Alcohol? | TDR Ca...  🎬    • DEA Hearing Ends: What Happens Next? | TDR...  Want to stay updated on Cannabis, Small Cap, AI, and Crypto?Subscribe to our Daily Baked newsletter:https://newsletter.thedalesreport.com...Find us on social media and podcast platforms:✅ Facebook:   / thedalesreport  ✅ Twitter:   / thedalesreport  ✅ Instagram:   / dalesreport  ✅ LinkedIn:   / the-dales-report  Apple Podcasts: https://tinyurl.com/TDRTradetoBlackon...Spotify: https://tinyurl.com/TDRTradeToBlackon...Website: https://thedalesreport.com/For copyright matters, contact:sdales@thedalesreport.comPodcast Disclaimer (Financial Interests)The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company, organization, or employer. The content is provided for informational and entertainment purposes only and should not be taken as financial, investment, or legal advice.The hosts and/or guests may hold positions in the companies, stocks, or financial instruments discussed during the show. These holdings should not be considered endorsements or recommendations to buy or sell any securities. Listeners are encouraged to do their own research or consult with a qualified financial advisor before making any investment decisions.By listening to this podcast, you agree that the hosts, guests, and producers are not liable for any decisions made based on the information discussed.Full Disclosures: https://thedalesreport.com/website-te...